50-56-6

• 常用中文名：催产素
• 常用英文名：Oxytocin acetate salt
• CAS号：50-56-6
• 分子式：C₄₃H₆₆N₁₂O₁₂S₂
• 分子量：1007.187
• 相关类别： 原料药 激素及调节内分泌功能类药 垂体激素类药
• 发布时间：2018-02-07 08:00:00
• 更新时间：2025-09-29 17:50:37
• 子宫收缩药。用于引产、催产、产后及流产后因宫缩无力等引起的子宫出血。滴鼻可促使排乳。
  不良反应和禁忌：分娩时，明显头盆不称、脐带先露或脱垂、完全性前置胎盘、骨盆过窄、宫缩过强禁用。胎盘早剥、心脏病、子宫过大、孕妇超过35岁、有剖腹产史、子宫肌瘤剔除术史及臀位产者慎用。骶管阻滞时用缩宫素，可发生严重的高血压，甚至脑血管破裂。不能与去甲肾上腺素合在同一溶液内注射。与水解蛋白有配伍禁忌。

名称

• 中文名: 催产素
• 英文名: Oxytocin
• 中文别名: 缩宫素; 醋酸催产素; N-苄氧羰基-S-苄基半胱氨酰酪氨酰异亮氨酰谷氨酰胺酰天冬酰胺酰(S-苄基)半胱氨酰脯氨酰
• 英文别名: Pitocin; Synpitan; α-Hypophamine Oxytocic hormone; Oxystin; L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic (1®6)-disulfide; Uteracon; Syntocinone; MFCD00076731; EINECS 200-048-4; (2S)-1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-N-{(1S)-1-[(2-amino-2-oxoethyl)carbamoyl]-3-methylbutyl}pyrrolidine-2-carboxamide; 1-{[(4R,7S,10S,13S,16S,19R)-19-Amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-2-butanyl]-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-L-leucylglycinamide; α-Hypophamine; Oxtocin; Nobitocin S; 1-{[(4R,7S,10S,13S,16S,19R)-19-Amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-L-leucylglycinamide; Atonin O; Syntocinon; Di-sipidin; Presoxin; Syntocin; Utedrin; Partocon; Oxytocin Acetate

物化性质

• 密度: 1.3±0.1 g/cm3
• 沸点: 1533.3±65.0 °C at 760 mmHg
• 熔点: 192-194°C
• 分子式: C₄₃H₆₆N₁₂O₁₂S₂
• 分子量: 1007.187
• 闪点: 881.1±34.3 °C
• 精确质量: 1006.436462
• PSA: 450.13000
• LogP: -4.26
• 外观性状: 冻干的粉末
• 蒸汽压: 0.0±0.3 mmHg at 25°C
• 折射率: 1.554
• 储存条件:

  棕色玻璃瓶闭光密封包装。贮存于低温干燥处。

• 计算化学:

  1、 疏水参数计算参考值（XlogP）：-2.6

  2、 氢键供体数量：12

  3、 氢键受体数量：13

  4、 可旋转化学键数量：17

  5、 互变异构体数量：1001

  6、 拓扑分子极性表面积（TPSA）：400

  7、 重原子数量：69

  8、 表面电荷：0

  9、 复杂度：1870

  10、同位素原子数量：0

  11、确定原子立构中心数量：9

  12、不确定原子立构中心数量：0

  13、确定化学键立构中心数量：0

  14、不确定化学键立构中心数量：0

  15、共价键单元数量：1

• 更多: 1. 性状：为白色无定形粉末，微有异臭 2. 密度（g/mL,25/4℃）：未确定

  3. 相对蒸汽密度（g/mL,空气=1）：未确定

  4. 熔点（ºC）：192-194°C

  5. 沸点（ºC,常压）：未确定

  6. 沸点（ºC, 5.2 kPa）：未确定

  7. 折射率：未确定

  8. 闪点（ºC）：未确定

  9. 比旋光度（º）：-26.2°, C=0.53, DIOXANE

  10. 自燃点或引燃温度（ºC）：未确定

  11. 蒸气压（kPa,25 ºC）：未确定

  12. 饱和蒸气压（kPa,60 ºC）：未确定

  13. 燃烧热（KJ/mol）：未确定

  14. 临界温度（ºC）：未确定

  15. 临界压力（KPa）：未确定

  16. 油水（辛醇/水）分配系数的对数值：未确定

  17. 爆炸上限（%,V/V）：未确定

  18. 爆炸下限（%,V/V）：未确定

  19. 溶解性：易溶于水，溶于丙酮、丁醇和稀醋酸，不溶于乙醚和石油醚

生物活性

• 描述: Oxytocin (α-Hypophamine)是哺乳动物神经脑垂体激素,能特异地与催产素受体高亲和性结合。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 催产素受体
  研究领域 >> 内分泌
• 参考文献:

  [1]. Oxytocin, From Wikipedia

MSDS

Section 1. Chemical Product and Company Identification Oxytocin Common Name/ Trade Name Manufacturer Oxytocin Section 4. First Aid Measures Eye ContactCheck for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Cold water may be used. Get medical attention if irritation occurs. Skin ContactWash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops. Cold water may be used. Serious Skin ContactNot available. InhalationIf inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention. Serious InhalationNot available. IngestionIf swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Loosen tight clothing such as a collar, tie, belt or waistband. Get medical attention immediately. Serious IngestionNot available. Section 5. Fire and Explosion Data Flammability of the Product May be combustible at high temperature. Auto-Ignition Temperature Not available. Flash PointsNot available. Flammable LimitsNot available. These products are carbon oxides (CO, CO2), nitrogen oxides (NO, NO2...), sulfur oxides (SO2, SO3...). Products of Combustion Fire Hazards in Presence of Slightly flammable to flammable in presence of heat. Various Substances Explosion Hazards in Presence Risks of explosion of the product in presence of mechanical impact: Not available. of Various SubstancesRisks of explosion of the product in presence of static discharge: Not available. Fire Fighting MediaSMALL FIRE: Use DRY chemical powder. and InstructionsLARGE FIRE: Use water spray, fog or foam. Do not use water jet. Special Remarks onAs with most organic solids, fire is possible at elevated temperatures. Fire HazardsMaterial in powder form, capable of creating a dust explosion. Special Remarks on Explosion Fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust Hazardsexplosion hazard. Section 6. Accidental Release Measures Small SpillUse appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on the contaminated surface and dispose of according to local and regional authority requirements. Large Spill Poisonous solid. Stop leak if without risk. Do not get water inside container. Do not touch spilled material. Use water spray to reduce vapors. Prevent entry into sewers, basements or confined areas; dike if needed. Eliminate all ignition allow to evacuate through the sanitary system. Oxytocin Section 7. Handling and Storage PrecautionsKeep away from heat. Keep away from sources of ignition. Ground all equipment containing material. Do not ingest. Do not breathe dust. Wear suitable protective clothing. If ingested, seek medical advice immediately and show the container or the label. StorageKeep container tightly closed. Keep container in a cool, well-ventilated area. Do not store above 8°C (46.4°F). Refrigerate. Section 8. Exposure Controls/Personal Protection Engineering ControlsUse process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants below the exposure limit. Personal ProtectionSafety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves. Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used a Large Spillto avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this product. Exposure LimitsNot available. Section 9. Physical and Chemical Properties Physical state and appearance Solid. (Powdered solid.)OdorNot available. TasteNot available. Molecular Weight1007.19 g/mole ColorWhite. Off-white. pH (1% soln/water)Not available. Not available. Boiling Point Melting PointNot available. Not available. Critical Temperature Specific GravityNot available. Vapor PressureNot applicable. Vapor DensityNot available. VolatilityNot available. Odor ThresholdNot available. Water/Oil Dist. Coeff.Not available. Ionicity (in Water)Not available. Dispersion PropertiesSee solubility in water. SolubilitySoluble in cold water. Soluble in 1-Butanol and 2-Butanol Section 10. Stability and Reactivity Data StabilityThe product is stable. Not available. Instability Temperature Conditions of InstabilityExcess heat Incompatibility with variousNot available. substances CorrosivityNot available. Oxytocin Special Remarks onNot available. Reactivity Special Remarks onNot available. Corrosivity PolymerizationWill not occur. Section 11. Toxicological Information Routes of EntryInhalation. Ingestion. Toxicity to AnimalsAcute oral toxicity (LD50): >20.52 mg/kg [Rat]. Chronic Effects on Humans Not available. Other Toxic Effects onSlightly hazardous in case of skin contact (irritant), of ingestion, of inhalation. Humans Special Remarks on Not available. Toxicity to Animals Special Remarks onMay cause adverse reproductive effects and birth defects (teratogenic) Chronic Effects on Humans Special Remarks on otherAcute Potential Health Effects: Toxic Effects on HumansSkin: May cause skin irritation. Eyes: May cause eye irritation. Inhalation: Dust may cause respiratory tract irritation. Ingestion: May be harmful if swallowed. May cause flushing, headache, somnolence, nausea and vomiting. May also cause hypotension followed by hypertension, bradycardia, tachycardia, arteriospasm, fluid and electrolyte imbalance, and possible seizures. It may also affect the kidneys. Blurred vision and conjunctival hemorrhage, anxiety, difficulty breathing are rare complications. Chronic Potential Health Effects: Ingestion: Prolonged or repeated ingesiton may cause allergic (anaphylactoid) reaction. Note: Uterine rupture or tears may result from high dose Oxytocin. The use of Oxytocin to induce labor may result in intrauterine transplacental hyponatremia which may cause neonatal seizures and respiratory depression. It may also cause neonatal hyperbilirubinemia and jaundice (effects on the liver). Section 12. Ecological Information Not available. Ecotoxicity Not available. BOD5 and COD Products of BiodegradationPossibly hazardous short term degradation products are not likely. However, long term degradation products may arise. Toxicity of the ProductsThe products of degradation are less toxic than the product itself. of Biodegradation Not available. Special Remarks on the Products of Biodegradation Section 13. Disposal Considerations Waste DisposalWaste must be disposed of in accordance with federal, state and local environmental control regulations. Oxytocin Section 14. Transport Information DOT ClassificationNot a DOT controlled material (United States). IdentificationNot applicable. Not applicable. Special Provisions for Transport DOT (Pictograms) Section 15. Other Regulatory Information and Pictograms No products were found. Federal and State Regulations CaliforniaCalifornia prop. 65: This product contains the following ingredients for which the State of California has found to cause cancer which would require a warning under the statute: No products were found. Proposition 65 Warnings California prop. 65: This product contains the following ingredients for which the State of California has found to cause birth defects which would require a warning under the statute: No products were found. Other RegulationsOSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200). EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances (EINECS No. 200-048-4). Canada: Listed on Canadian Domestic Substance List (DSL). China: Not listed on National Inventory. Japan: Listed on National Inventory (ENCS). Korea: Not listed on National Inventory (KECI). Philippines: Not listed on National Inventory (PICCS). Australia: Listed on AICS. WHMIS (Canada) CLASS D-2A: Material causing other toxic effects (VERY TOXIC). Other Classifications DSCL (EEC)R22- Harmful if swallowed.S46- If swallowed, seek medical advice immediately and show this container or label. Health Hazard HMIS (U.S.A.)1 National Fire Protection 1 Flammability 1 Association (U.S.A.) Fire Hazard 1 0 Reactivity Health Reactivity 0 Specific hazard Personal Protection E WHMIS (Canada) (Pictograms) DSCL (Europe) (Pictograms) TDG (Canada) (Pictograms) Oxytocin ADR (Europe) (Pictograms) Protective Equipment Gloves. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : RS7534000 CHEMICAL NAME : Oxytocin CAS REGISTRY NUMBER : 50-56-6 LAST UPDATED : 199612 DATA ITEMS CITED : 29 MOLECULAR FORMULA : C43-H66-N12-O12-S2 MOLECULAR WEIGHT : 1007.33 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >20520 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,230,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >20520 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,230,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2275 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,230,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >514 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,230,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >514 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,230,1990 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5800 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,151,1982 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 82 ng/kg SEX/DURATION : female 37 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow) REFERENCE : ADCHAK Archives of Disease in Childhood. (British Medical Journal, POB 560B, Kennebunkport, ME 04046) V.1- 1926- Volume(issue)/page/year: 54,400,1979 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 5760 uL/kg SEX/DURATION : female 39 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Specific Developmental Abnormalities - hepatobiliary system Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) REFERENCE : PPATDQ Pediatric Pathology. (Hemisphere Publishing Corp., c/o Taylor & Francis Inc., 1900 Frost Rd., Suite 101, Bristol, PA 19007) V.1- 1983- Volume(issue)/page/year: 12,761,1992 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 20 ug/kg SEX/DURATION : female 21 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 8,181,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 650 ng/kg SEX/DURATION : female 21 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 9,651,1975 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 30000 iu/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Maternal Effects - other effects REFERENCE : ACENA7 Acta Endocrinologica (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) V.1- 1948- Volume(issue)/page/year: 125,109,1991 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 277 ng/kg SEX/DURATION : female 21 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 5,941,1971 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 10 units/kg SEX/DURATION : female 15 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - abortion REFERENCE : JOETD7 Journal of Ethnopharmacology. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1979- Volume(issue)/page/year: 23,27,1988 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant DOSE : 175 ug/kg SEX/DURATION : female 17-21 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - other neonatal measures or effects REFERENCE : JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939- Volume(issue)/page/year: 101,121,1984 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant DOSE : 175 ug/kg SEX/DURATION : female 17-21 day(s) after conception lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939- Volume(issue)/page/year: 101,121,1984 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant DOSE : 500 ug/kg SEX/DURATION : female 17 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical REFERENCE : NETEEC Neurotoxicology and Teratology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.9- 1987- Volume(issue)/page/year: 15,383,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal DOSE : 500 ng/kg SEX/DURATION : female 18 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - live birth index (measured after birth) REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 8,181,1974 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 80 ug/kg SEX/DURATION : female 19 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition REFERENCE : BJPCBM British Journal of Pharmacology. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.34- 1968- Volume(issue)/page/year: 36,188P,1969 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 80 ug/kg SEX/DURATION : female 19 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition REFERENCE : BJPCBM British Journal of Pharmacology. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.34- 1968- Volume(issue)/page/year: 36,188P,1969 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 80 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina REFERENCE : PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04- Volume(issue)/page/year: 133,1254,1970 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 900 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - other effects REFERENCE : CCPTAY Contraception. (Geron-X, Inc., POB 1108, Los Altos, CA 94022) V.1- 1970- Volume(issue)/page/year: 28,267,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 300 mg/kg SEX/DURATION : female 6-20 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) REFERENCE : CEFYAD Ceskoslovenska Fysiologie. (Academia, Vodickova 40, 112 29 Prague 1, Czechoslovakia) V.1- 1952- Volume(issue)/page/year: 38,278,1989 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 150 ng/kg SEX/DURATION : male 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) REFERENCE : ENDOAO Endocrinology (Baltimore). (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21203) V.1- 1917- Volume(issue)/page/year: 73,433,1963 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 2400 ng/kg SEX/DURATION : female 63-64 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - abortion REFERENCE : ACEDAB Acta Endocrinologica, Supplementum (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) No.1- 1948- Volume(issue)/page/year: 253,148,1983 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 24 ug/kg SEX/DURATION : lactating female 1 day(s) post-birth TOXIC EFFECTS : Reproductive - Maternal Effects - postpartum REFERENCE : JRPFA4 Journal of Reproduction and Fertility. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1960- Volume(issue)/page/year: 23,537,1970 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 1613 mg/kg SEX/DURATION : female 18-19 week(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow) REFERENCE : AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 160,242,1989 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 50 ug/kg SEX/DURATION : female 1 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition REFERENCE : BVJOA9 British Veterinary Journal. (Bailliere Tindall, 33 The Avenue, Eastbourne BN21 3UN, UK) V.105- 1949- Volume(issue)/page/year: 146,577,1990 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 54 ng/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Maternal Effects - menstrual cycle changes or disorders REFERENCE : JRPFA4 Journal of Reproduction and Fertility. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1960- Volume(issue)/page/year: 18,259,1969 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3710 No. of Facilities: 113 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 2515 (estimated) No. of Female Employees: 1568 (estimated)

安全

• 危害码 (欧洲): Xi: Irritant;
• 风险声明 (欧洲): R36/37/38
• 安全声明 (欧洲): 26-36
• 危险品运输编码: 3249
• WGK德国: 3
• RTECS号: RS7534000
• 包装等级: II
• 危险类别: 6.1(a)

合成路线

151937-33-6 ~99% 50-56-6

文献：Tovi, Avi; Eidelman, Chaim; Shushan, Shimon; Elster, Shai; Alon, Hagi; Ivchenko, Alexander; Butilca, Gabriel-Marcus; Zaovi, Gil Patent: US2006/148699 A1, 2006 ; Location in patent: Page/Page column 11 ;

41089-31-0 ~% 50-56-6

文献：Wang, Ting; Danishefsky, Samuel J. Journal of the American Chemical Society, 2012 , vol. 134, # 32 p. 13244 - 13247

27610-07-7 ~% 50-56-6

文献：Wang, Ting; Danishefsky, Samuel J. Journal of the American Chemical Society, 2012 , vol. 134, # 32 p. 13244 - 13247

27560-15-2 ~% 50-56-6

文献：Wang, Ting; Danishefsky, Samuel J. Journal of the American Chemical Society, 2012 , vol. 134, # 32 p. 13244 - 13247

118408-13-2 ~% 50-56-6

文献：Wang, Ting; Danishefsky, Samuel J. Journal of the American Chemical Society, 2012 , vol. 134, # 32 p. 13244 - 13247

上下游产品

上游产品  3
41089-31-0 27610-07-7 118408-13-2
下游产品  1
407-25-0

制备

缩宫素液的提取 取后叶干粉100g，石英粉30g放人球磨机中，加入蒸馏水，同法提取四次。加入蒸馏水的量依次为1.4L两次，1.3L两次。每次提取45min，离心，收集液体，残渣再进行提取。合并四次提取液，即得缩宫素液。
后叶干粉[水，球磨机]→缩宫素提取液
层析分离 将事先处理好的人造沸石1500g，加入20L的0.25%乙酸溶液，搅拌后倒人交换柱中，待乙酸液下降至沸石表面以上2-3cm处时，即加入提取液，于适当流速下收集白色浑浊液(主要含缩宫素，因其pI7.7，而加压素 pI10.9，易成为正离子而被吸附)。当提取液液面下降到沸石表面时，立即加入蒸馏水，继续收集浑浊液，直到流尽为止。将浑浊液用冰醋酸调pH为3.5，于水浴迅速加热至95℃保持3min，迅速冷却并冷藏过夜。
缩宫素提取液[HAc, 人造沸石柱]→浑浊液[HAc, 加热]→分离液
吸附、洗脱 次日，将冷藏液过滤，滤液在搅拌下加入10%皂土浆 (每100ml加3ml)，搅拌1h吸附，离心。上清液用磺基水杨酸试液检查，不发生沉淀为吸附完全。若不完全，再次吸附，合并两次皂土浆沉淀。皂土用1%乙酸分四次洗脱(分别为1.6L、1.4L、1.2L、0.8L)，每次的洗脱液加热到80℃时加入三氯叔丁醇，再升温至95℃，速冷至25℃，过滤或离心，合并四次滤液，检测效价和加压素限度。
冷藏液[过滤]→滤液[皂土浆]→吸附物[1% HAc]→洗脱液
缩宫素注射液的制备 将测得的合格缩宫素液，稀释到5U/ml或10U/ml，经4号或5号垂熔漏斗过滤，灌封，100℃流通蒸气灭菌30min，即得成品。
缩宫素液（测定合格）[过滤灌封，灭菌]→缩宫素注射液。
注：人造沸石处理 新沸石经60-80目筛后，每500g加2L蒸馏水，氢氧化钠调至pH9，保持半小时，倾去上清液，再加水2L，调至pH9，再倾去上清液，加水，搅拌并加稀硫酸使pH下降到5.8-6搅拌半小时，倾去上清液，再每次用儿水，反复洗7-8次。加水1L和稀硫酸，搅拌半小时，倾去上清液，用水洗至pH7，滤干，干燥备用。
人造沸石的再生 将人造沸石用蒸馏水洗2次，然后加1.5L的水(按沸石500g计算)和氯化钠150g搅拌2h，洗涤除去加压素，再用蒸馏水洗到无氯离子为止。加适量水，用氢氧化钠调节pH至9，搅拌半小时，倾去上清液，用蒸馏水洗涤，以硫酸调节pH至5.5-6，再用水洗至近中性，滤干，在105℃烘干备用。用前加适量水，并用冰醋酸调节，搅拌浸泡。
10%皂土浆的制备 按皂土质量与水的体积比为1:10的比例混合，研磨约1h，并在研磨中用乙酸调节pH稳定在3.5，放置冰箱中备用。
方法二、化学合成法
先从苄氧碳酰亮氨酸对硝基苯酯合成7肽酰胺(3-9段)，再合成苄氧羰酰-S-苄基半胱·酪氨酰叠氮(1-2段)，第三步合成缩宫素。